KHKatja von Hoff

Katja von Hoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katja von Hoff has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • MBCL-45. ROLE OF IRRADIATION IN RELAPSED MEDULLOBLASTOMA: A REPORT OF THE GERMAN MEDULLOBLASTOMA RELAPSE STUDIES

    by Stephan Tippelt, Julia Küter, Ruth Mikasch, Nele Siegler, Monika Warmuth-Metz, Stefan Rutkowski, Martin Mynarek, Katja von Hoff, Torsten Pietsch, Stefan M Pfister, et al.

    In pediatric patients with medulloblastoma (MB) the 5-year-OS rate dependent on risk group is 35% to 90%. In unresectable or metastatic recurrence longterm prognosis is poor. Aim of this study was to evaluate the role of irradiation in relapsed MB patients registered in the German studies HIT-MED, HIT-REZ-97/-2005 and HIT-REZ-Registry between July 1997 and December 2016. Data analyzed at relapse were age, gender, stage, primary/relapse therapy, and follow-up. Kaplan-Meier analysis and log rank test were used to estimate the PFS/OS after 1st recurrence and (re)irradiation. 257 patients with recurrent/refractory MB [75 female/182 male, median age 11.0 years (0.8-37.9), median PFS after 1st diagnosis 24.8 months (2.6-270.2), 81% metastatic disease at relapse] were included in this analysis. Median PFS and OS after first relapse were 12.3 months (95%CI: 9.4;15.2) and 23.8 months (95%CI: 19.3-28.3), the 5-year-PFS and 5-year-OS rate were 6.8%±1.7% and 19.3%±2.7%, respectively. The PFS and OS differed significantly between 4 different cohorts: patients (A) with 1st irradiation at 1st relapse (n=29), (B) with re-irradiation (n=54), (C) without re-irradiation at 1st relapse (n=164), and (D) without irradiation at any time (10). The best 5-year-PFS and 5-year-OS rate were observed in cohort A with 20.1% ±7.8 and 34.2% ±9.3, respectively. Looking for different strata significant differences were seen in patients with metastatic disease. Radiotherapy at relapse can be used as salvage therapy in patients without primary irradiation. It can lead to prolonged PFS and OS especially in patients with metastatic disease. Supported by German Children’s Cancer Foundation.

  • MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY

    by Martin Mynarek, Marcel Kool, Ulrich Schueller, Katja von Hoff, Tanvi Sharma, Vasilisa Rudneva, Torsten Pietsch, Paul Northcott, B -Ole Juhnke, Barbara Meissner, et al.

    Methylation-based tumor classification results were obtained from 86 patients younger than four years with medulloblastoma treated with systemic chemotherapy and intraventricular methotrexate to avoid craniospinal radiotherapy (CSI). 70 were HIT trial participants and 16 observational patients. Subgroup specific survival was analyzed. Median follow-up was 8.3 years in the 61 patients alive at last follow-up. 33 patients presented with metastatic disease. Methylation profiling results were WNT (n=1), SHH_INF (n=43), Group 3 (GRP3; n=32) and Group 4 (GRP4; n=10). Of 39 patients with desmoplastic/nodular histology, 38 patients had SHH_INF, one GRP4 medulloblastoma. Survival differed significantly according to methylation subgroup (5y-PFS WNT: 0%, SHH_INF: 79%, GRP3: 31%, GRP4: 70%, p<0.001; 5y-OS: WNT 100%, SHH_INF: 95%, GRP3: 43%, GRP4: 100%, p<0.001). Within the SHH_INF subgroup, no additional risk factors were identified (SHH-I [n=23] vs. SHH-II [n=20; p=0.767(PFS)/0.177(OS)], chromosome 2 gain [n=10; p=0.123(PFS)/0.430(OS)], chromosome 9q loss [n=16; p=0.904(PFS)/0.224(OS)]). In GRP3 medulloblastoma, neither MYC-amplification (n=11, p=0.172[PFS]/0.064[OS]) nor metastatic disease (n=17; p=0.710[PFS]/0.971[OS]) predicted survival. 5-year radiotherapy free survival (CSI or local RT) was WNT: 0%, SHH_INF: 81%, GRP3: 6% and GRP4: 40%; p<0.001. In contrast to previously reported poor outcomes in patients with SHH-infant medulloblastoma subgroup SHH-I when treated with systemic chemotherapy alone, chemotherapy with intraventricular methotrexate was effective and avoided CSI in both SHH infant subgroups. The role of intraventricular MTX in this context needs further evaluation. Outcome for GRP3 medulloblastoma was poor, independent of other risk factors. Patients with GRP3 or GRP4 medulloblastoma frequently received radiotherapy for relapsing or non-responsive disease.

  • MBCL-39. MEDULLOBLASTOMA IN PATIENTS WITH GORLIN SYNDROME: RESULTS FROM THE HIT STUDY GROUP

    by Barbara Meissner, Martin Mynarek, B Ole Juhnke, Katja von Hoff, Torsten Pietsch, Rolf D Kortmann, Monika Warmuth-Metz, Brigitte Bison, Stefan Rutkowski

    Gorlin syndrome is an autosomal dominant inherited cancer predisposition syndrome characterized by basal cell carcinomas, odontogenic keratocysts, skeletal and multiple other anomalies, and medulloblastoma (MB). Most patients harbor a heterozygous germline mutation in PTCH1 or SUFU, genes that play a pivotal role in sonic hedgehog (SHH) signaling. We describe 17 patients with Gorlin syndrome diagnosed with MB between 1992 and 2017 who were treated according to HIT studies (HIT’91, SKK’92, HIT2000, and I-HIT-MED registry) and had available data on initial staging and treatment. Diagnosis of Gorlin syndrome was made clinically by fulfilling the syndrome criteria (N=9) or by proven PTCH1 (N=7) or SUFU (N=3) germline mutation. Median age at diagnosis of MB was 0.96 years. MB with extensive nodularity (N=5) and desmoplastic medulloblastoma (N=11) were the predominant histologic diagnoses, both typically associated with sonic hedgehog pathway activation (classical MB N=1). 12 of 17 patients had localized disease, 5 patients had metastases at initial diagnosis. 16 patients received HIT-SKK chemotherapy alone, 1 had primary craniospinal radiotherapy. HIT-SKK therapy was reduced in 3 patients with increased toxicities. Median follow up was 10.3 years. All patients are alive, two suffered from relapse 1.5 and 1.7 years after initial diagnosis. 10 year progression free survival was 82%±12%. Basal cell carcinoma was diagnosed in 2 patients, who were treated with radiotherapy. Gorlin syndrome and genetic counselling should be considered in all young children with SHH activated MB. Radiotherapy can be successfully avoided in most patients by HIT-SKK chemotherapy and is contraindicated within first-line therapy strategies.


  • EMBR-12. IMPROVED DIAGNOSTIC ALGORITHM FOR DIFFERENTIAL DIAGNOSTICS OF CNS EMBRYONAL TUMORS (FORMER CNS-PNET) BY NEUROPATHOLOGICAL RE-EVALUATION OF 256 CASES AND CROSSVALIDATION BY METHYLATION CLASSIFICATION

    by Torsten Pietsch, Dominique Figarella-Branger, Felice Giangaspero, Marco Gessi, Cynthia Hawkins, Thomas Jacques, Andrey Korshunov, Charles Eberhart, Peter Burger, Katja von Hoff, et al.

    Epigenetic profiling has shown that a proportion of cases diagnosed as CNS PNET in the past can be assigned to other tumour entities with similar morphological appearance. In an international effort to re-analyze CNS-PNET aiming for disease-specific re-evaluation of survival data and the development of diagnostic guidelines providing the basis for improved therapeutic approaches, 256 tumours diagnosed and treated as CNS-PNET in the last two decades in 17 countries were reviewed by a panel of neuropathologists according to today’s standards of clinical neuropathological diagnostics including immunohistochemical and molecular pathological assays. The majority of cases were also independently analyzed by methylation array hybridization and classified by random forest algorithm. In this unique cohort, we identified 20 different tumor entities including frequent high grade gliomas. 41% of cases were confirmed as CNS-PNET (now termed CNS-embryonal tumors (CNS-ET) according to the revised WHO-classification) representing two main entities: ETMR displayed typical histopathological features, LIN28A expression and/or C19MC alteration. The other represented a group of tumors with variable degrees of differentiation along neuroblastic/ganglionic lines, corresponding to the WHO diagnoses CNS-(Ganglio)-neuroblastoma or CNS-ET, NOS. The vast majority of these tumors could be assigned to the FOXR2 CNS-NB group by methylation array-based classification. Crossvalidation of neuropathological and epigenetic classification proved that methylation classification represents a useful complimentary tool in the differential diagnosis of CNS-ET. Re-evaluation of prototypic tumors and cases with discrepant diagnoses enabled us to develop an optimized diagnostic algorithm to securely delineate this tumor type from other entities with largely divergent clinical and biological behaviour.

  • Neuropsychological short assessment of disease- and treatment-related intelligence deficits in children with brain tumours

    by Holger Ottensmeier, Bernhard Zimolong, Johannes E. Wolff, Jochen Ehrich, Niels Galley, Katja von Hoff, Joachim Kuehl, Stefan Rutkowski


  • Frequency, Risk‐Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German HIT Database

    by Katja von Hoff, Bernward Hinkes, Elke Dannenmann‐Stern, André O. von Bueren, Monika Warmuth‐Metz, Niels Soerensen, Angela Emser, Isabella Zwiener, Paul G. Schlegel, Joachim Kuehl, et al.

    Purpose: To analyze the frequency, prognostic factors, and outcome of children with atypical teratoid/rhabdoid tumors (AT/RT), a rare and highly malignant embryonal brain tumor.Materials and Methods: Clinical data of patients diagnosed between 1988 and 2004 with AT/RT who were registered to the German HIT trial center, were correlated with outcome. Patient numbers for AT/RT were compared to numbers for primitive neuroectodermal tumors and medulloblastomas (PNET/MB) registered to the population‐based HIT trials.Results: We identified 56 patients with the centrally confirmed histopathological diagnosis of AT/RT with a median age of 1.2 years (range, 0.1–14.0 years). The AT/RT:PNET/MB ratio was 1:12.2 for all children, and 1:1.5 for children younger than 1 year at diagnosis. Three‐year overall survival (OS) and event‐free survival (EFS) for all patients were 22% and 13%, respectively. Eight patients (14%) are considered long‐term event‐free survivors (follow‐up 1.4–10.6 years). By univariable analyses, younger age, metastatic disease, infratentorial location, and less than complete remission at the end of chemotherapy were identified as negative influencing factors for OS. By multivariable analyses, younger age (OS, EFS) and metastatic disease (OS) were identified as independent risk factors.Conclusion: The incidence of AT/RT in children below 1 year is higher than previously reported. A subset of patients with favorable clinical risk factors profits from intensive multimodal treatment. Prospective clinical and biological studies are needed to further define prognostic factors and optimize therapy. Pediatr Blood Cancer 2011; 57: 978–985.